Association of blood n-3 fatty acid with bone mass and bone marrow TRAP-5b in the elderly with and without hip fracture
The plasma n-3 fatty acid level was 26.2% lower in patients with osteoporotic hip fracture than in those with osteoarthritis. In all patients, n-3 fatty acid was positively associated with bone mineral density and inversely associated with tartrate-resistant acid phosphatase-5b level in bone marrow aspirates, reflecting the bone microenvironment.
Despite the potential beneficial role of n-3 fatty acid (FA) on bone metabolism, the specific mechanisms underlying these effects in humans remain unclear. Here, we assessed whether the plasma n-3 level, as an objective indicator of its status, is associated with osteoporosis-related phenotypes and bone-related markers in human bone marrow (BM) samples.
This was a case-control and cross-sectional study conducted in a clinical unit. n-3 FA in the blood and bone biochemical markers in the BM aspirates were measured by gas chromatography/mass spectrometry and immunoassay, respectively. BM fluids were collected from 72 patients who underwent hip surgery because of either osteoporotic hip fracture (HF; n = 28) or osteoarthritis (n = 44).
After adjusting for confounders, patients with HF had 26.2% lower plasma n-3 levels than those with osteoarthritis (P = 0.006), and each standard deviation increment in plasma n-3 was associated with a multivariate-adjusted odds ratio of 0.40 for osteoporotic HF (P = 0.010). In multivariate analyses including all patients, a higher plasma n-3 level was associated with higher bone mass at the lumbar spine (β = 0.615, P = 0.002) and total femur (β = 0.244, P = 0.045). Interestingly, the plasma n-3 level was inversely associated with the tartrate-resistant acid phosphatase-5b level (β = − 0.633, P = 0.023), but not with the bone-specific alkaline phosphatase level, in BM aspirates.
These findings provide clinical evidence that n-3 FA is a potential inhibitor of osteoclastogenesis that favors human bone health.
KeywordsBone mass Bone resorption n-3 fatty acid Osteoporotic fracture
This study was supported by a grant from the Bio & Medical Technology Development Program of the National Research Foundation, funded by the Korean government, MSIP (2016M3A9E8941329).
Compliance with ethical standards
This study was approved by the Institutional Review Board of Asan Medical Center and was conducted according to the Ethical Principles for Medical Research Involving Human Subjects as defined by the Helsinki Declaration.
All participants in this study provided informed consent.
Conflicts of interest
- 6.Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, Ringel A, Davis JM, Hibbeln JR (2013) Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ (Clin Res Ed) 346:e8707Google Scholar
- 7.Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C (2012) Health implications of high dietary omega-6 polyunsaturated fatty acids. J Nutr Metabol 2012:539426Google Scholar
- 19.(2001) Guidance for Industry: Bioanalytical Method Validation. In US Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) (ed)Google Scholar
- 20.Virtanen JK, Mozaffarian D, Willett WC, Feskanich D (2012) Dietary intake of polyunsaturated fatty acids and risk of hip fracture in men and women. Osteoporos Int 23:2615–2624Google Scholar
- 26.Harris TB, Song X, Reinders I, Lang TF, Garcia ME, Siggeirsdottir K, Sigurdsson S, Gudnason V, Eiriksdottir G, Sigurdsson G, Steingrimsdottir L, Aspelund T, Brouwer IA, Murphy RA (2015) Plasma phospholipid fatty acids and fish-oil consumption in relation to osteoporotic fracture risk in older adults: the Age, Gene/Environment Susceptibility Study. Am J Clin Nutr 101:947–955CrossRefGoogle Scholar
- 28.Ahn SH, Park SY, Baek JE, Lee SY, Baek WY, Lee SY, Lee YS, Yoo HJ, Kim H, Lee SH, Im DS, Lee SK, Kim BJ, Koh JM (2016) Free fatty acid receptor 4 (GPR120) stimulates bone formation and suppresses bone resorption in the presence of elevated n-3 fatty acid levels. Endocrinology 157:2621–2635CrossRefGoogle Scholar